uniQure NV (FRA:UQ1) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of uniQure NV is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of uniQure NV's Risk Assessment

For the Biotechnology subindustry, uniQure NV's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Risk Assessment distribution charts can be found below:

* The bar in red indicates where uniQure NV's Risk Assessment falls into.

uniQure NV (FRA:UQ1) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

uniQure NV Risk Assessment Related Terms

Thank you for viewing the detailed overview of uniQure NV's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

uniQure NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (FRA:UQ1) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

QURE:USA 0EE0:UK UQ1:Germany

Address

Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP

Website

https://www.uniqure.com

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

uniQure NV Headlines

No Headlines